Previous 10 | Next 10 |
2023-03-09 14:52:53 ET Summary Given that Axsome Therapeutics, Inc. is launching Auvelity with a small in-house team, you can expect a substantial sales increase in the next three years. In a highly favorable deal, Axsome recently out-licensed its ex-USA rights of Sunosi to Pharma...
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Off...
Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q4 2022 Earnings Call Feb 27, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q4 2022 Earnings Call Transcript
The US FDA has asked Axsome Therapeutics ( NASDAQ: AXSM ) to provide additional long-term safety data and information for AXS-05, its late-stage asset for Alzheimer's disease agitation. The agency wrote that the company should provide placebo-controlled safety information from the ong...
Axsome Therapeutics, Inc. (AXSM) Q4 2022 Earnings Conference Call February 27, 2023 08:00 AM ET Company Participants Mark Jacobson - COO Herriot Tabuteau - Chairman & CEO Nick Pizzie - CFO Lori Englebert - EVP, Commercial and Business Development Hunter Mur...
Axsome Therapeutics press release ( NASDAQ: AXSM ): Q4 GAAP EPS of -$1.41 misses by $0.28 . Revenue of $24.37M beats by $2.49M . Auvelity was launched on October 19, 2022 and had U.S. net sales of $5.2 million for the fourth quarter of 2022. No Auvelity sales...
Total fourth quarter net product sales of $24.4 million Auvelity ® launched October 19th, with fourth quarter net product sales of $5.2 million Sunosi ® fourth quarter net product sales of $19.2 million Sunosi ® license ...
Axsome Therapeutics ( NASDAQ: AXSM ) is scheduled to announce Q1 earnings results on Monday, February 27th, before market open. The consensus EPS Estimate is -$1.13 (-9.7% Y/Y) and the consensus Revenue Estimate is $21.88M Over the last 1 year, AXSM has beaten EPS estimates ...
Axsome Therapeutics ( NASDAQ: AXSM ) announced a licensing agreement with U.K.-based Pharmanovia on Wednesday for Sunosi, a medication indicated in Europe for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). Per the terms, Pharmanovia wil...
Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future clinical studies in Europe and MENA NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Axsome T...
News, Short Squeeze, Breakout and More Instantly...
Axsome Therapeutics Inc. Company Name:
AXSM Stock Symbol:
NASDAQ Market:
Axsome Therapeutics Inc. Website:
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this se...
2024-07-15 07:15:00 ET Any stock can have an impressive run, especially when broader equities are experiencing a bull market. Significantly fewer stocks can perform well through good and not-so-good times and deliver excellent returns over long periods. These are precisely the sort of corpo...
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of ...